Harrow- 11.875% NT REDEEM 31/12/2027 USD 25 Net Income

Harrow- 11.875% NT REDEEM 31/12/2027 USD 25 (HROWM) currently reports a net income of $-37M as of June 2026. That compares with $-10M in the prior-year period — down 264.0% year over year. That is below the Healthcare sector average of $16B. Use the charts on this page to explore Harrow- 11.875% NT REDEEM 31/12/2027 USD 25's net income history and peer comparisons.

Harrow- 11.875% NT REDEEM 31/12/2027 USD 25's net income decreased from $-10M to $-37M — a 264.0% year-over-year decrease (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Harrow- 11.875% NT REDEEM 31/12/2027 USD 25's net income of $-37M is lower than the Healthcare sector average of $16B. That is roughly 100.2% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

Harrow- 11.875% NT REDEEM 31/12/2027 USD 25 reported $-37M in net income as of June 2026. That compares with $-10M in the prior-year period — down 264.0% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current net income of $-37M, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $16B. From there, open related valuation or income-statement pages for Harrow- 11.875% NT REDEEM 31/12/2027 USD 25, and consider following HROWM for alerts when major investors trade the stock.